Literature DB >> 6827472

Assessment of 75/75 rule: FDA viewpoint.

B E Cabana.   

Abstract

Mesh：

Year:  1983        PMID： 6827472     DOI： 10.1002/jps.2600720127

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  6 in total

1.  Consideration of individual bioequivalence.

Authors:  S Anderson; W W Hauck
Journal:  J Pharmacokinet Biopharm       Date:  1990-06

2.  An overview about biopharmaceutics in Europe.

Authors:  Jean-Marc Aiache
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

3.  Assessment of variance in bioavailability studies: comments on the article by McNamara et al.

Authors:  C M Metzler
Journal:  Pharm Res       Date:  1987-12       Impact factor: 4.200

4.  Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.

Authors:  Michel Berg; Timothy E Welty; Barry E Gidal; Francisco J Diaz; Ron Krebill; Jerzy P Szaflarski; Barbara A Dworetzky; John R Pollard; Edmund J Elder; Wenlei Jiang; Xiaohui Jiang; Regina D Switzer; Michael D Privitera
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

5.  Between-lot and within-lot comparisons of bioavailability of macrocrystalline nitrofurantoin capsules.

Authors:  W D Mason; J D Conklin; F J Hailey
Journal:  Pharm Res       Date:  1987-12       Impact factor: 4.200

6.  Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study.

Authors:  P J McNamara; T S Foster; G A Digenis; R B Patel; W A Craig; P G Welling; R S Rapaka; V K Prasad; V P Shah
Journal:  Pharm Res       Date:  1987-04       Impact factor: 4.200
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.